Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Canine osteosarcoma: amputation and chemoimmunotherapy

E G MacEwen1, I D Kurzman

  • 1Department of Medical Sciences, University of Wisconsin, Madison 53706, USA.

The Veterinary Clinics of North America. Small Animal Practice
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.

Veterinary and comparative oncology·2016
Same author

Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.

Veterinary and comparative oncology·2015
Same author

Neurokinin-1 receptor expression and antagonism by the NK-1R antagonist maropitant in canine melanoma cell lines and primary tumour tissues.

Veterinary and comparative oncology·2014
Same author

Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.

Veterinary and comparative oncology·2014
Same author

Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma.

Veterinary and comparative oncology·2013
Same author

Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.

Journal of veterinary internal medicine·2012

For dogs with osteosarcoma, amputation combined with cisplatin chemotherapy and immunotherapy offers the longest survival time. This treatment combination significantly improves outcomes for canine cancer patients.

Area of Science:

  • Veterinary Oncology
  • Cancer Biology
  • Immunotherapy

Background:

  • Canine osteosarcoma is a prevalent and aggressive bone cancer in large breed dogs.
  • High metastatic potential at diagnosis (90-95% have micrometastases) leads to poor prognosis.
  • Current treatments like amputation alone or with chemotherapy offer limited survival benefits.

Purpose of the Study:

  • To evaluate the efficacy of a multi-modal treatment approach for canine osteosarcoma.
  • To determine if immunotherapy, following amputation and chemotherapy, further improves survival times.
  • To establish a new benchmark for adjuvant therapy in canine osteosarcoma.

Main Methods:

  • Dogs with osteosarcoma underwent amputation.
  • Post-operative treatment included cisplatin chemotherapy.

Related Experiment Videos

  • Adjuvant therapy consisted of liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (mTEP-LIP).

    • Main Results:

    • Amputation alone resulted in a median survival time of 3-4 months.
    • Amputation with cisplatin chemotherapy extended median survival to 9-11 months.
    • Amputation, cisplatin chemotherapy, and mTEP-LIP immunotherapy achieved a median survival of 14.4 months.

    Conclusions:

    • The combination of amputation, cisplatin chemotherapy, and mTEP-LIP immunotherapy represents the most effective adjuvant treatment strategy currently reported for canine osteosarcoma.
    • This multi-modal approach significantly prolongs survival in dogs diagnosed with this aggressive cancer.
    • Further research into immunotherapy combinations may yield even better outcomes for canine osteosarcoma patients.